University of California, San Francisco
San Francisco, California, 94010, United States
Location status: Recruiting
Location contact
Gerami D Seitzman, MD
CONTACT
Gerami D Seitzman, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06976515
Dry eye disease is a common problem that can make your eyes feel uncomfortable and affect your vision, making daily tasks harder. Many past studies on dry eye treatments haven't worked well because they didn't include enough people or different types of people. Doing studies at home instead of at the doctor's office can help more people join and make it easier to find out which treatments really work.
Interested in participating?
Request Info18 year and older
All sexes
Observational
San Francisco, California, 94010, United States
Location status: Recruiting
Gerami D Seitzman, MD
CONTACT
Gerami D Seitzman, MD
PRINCIPAL_INVESTIGATOR
This is a feasibility study, this is not an interventional study. This proposal outlines a novel approach to the study of dry eye disease through a decentralized clinical trial design. This non-interventional planning and feasibility proposal shifts the focus of dry eye disease study away from doctors' offices and into participants' home environments. Subjective dry eye disease symptoms are collected remotely, electronically, and sequentially. Self-collected ocular surface samples are collected in two ways: with a self-collected Schirmer strips and with a self-collected ocular surface swab of the eyelid margin and conjunctiva. All study materials are mailed to participants' homes. Self-collected ocular surface samples are placed in study vials and return-mailed by the participant to a central location, UCSF Proctor Foundation laboratory. Here, the samples are processed for RNA-deep sequencing which allows for host transcriptomic analysis. To mimic repeat ocular surface collection after a future dry eye disease intervention, Schirmer strips and ocular surface self-swabbing will be repeated after 4 weeks. This decentralized approach to dry eye disease study promotes patient engagement, recruitment, communication, and participant diversity and also seeks to identify new objective markers of dry eye disease efficacy that can be collected remotely.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4 weeks
The primary outcome is the rate of successful completion of the OSDI and SPEED surveys at two time points and the receipt of two clinical samples from two time points.
Time frame: 4 weeks
Time frame: 4 weeks
The measurement used to assess this outcome will be the quantity of recoverable human mRNA extracted from self-collected Schirmer strips, expressed as the total number of high-quality, aligned transcript reads per sample after RNA sequencing.
Time frame: 4 weeks
The measurement will be the expression levels of selected inflammatory cytokine genes, quantified as normalized transcript read counts derived from RNA sequencing data. Gene expression levels will be assessed at two time points, 4 weeks apart, with no intervention. Paired comparisons will be made to evaluate intra-participant variability and overall variance across the cohort.
Contact information is provided by the study sponsor or research team.
Brianna K Colado, BA
CONTACT
Gerami D Seitzman, MD
CONTACT
University of California, San Francisco
Other
Initial Cohort Study for Remote Investigation of Eye Dryness: A Pilot and Feasibility Study
Acronym: I CRIED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07705893
Dry Eye, Dry Eye Syndromes
Houston, Texas, United States
View Trial DetailsNCT07732010
Dry Eye Disease (DED), Dry Eye Syndromes
New York, United States
View Trial DetailsNCT07413172
Dry Eye, Dry Eye Syndromes
Miami, Florida, United States
View Trial DetailsNCT07722624
Dry Eye, Dry Eye Syndromes
Louisville, Kentucky, United States
View Trial Details